Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
Washington University School of Medicine
Children's Oncology Group
City of Hope Medical Center
Children's Oncology Group
Dana-Farber Cancer Institute
Emory University
Eli Lilly and Company
Medical University of Vienna
National Institutes of Health Clinical Center (CC)
Clinica Universidad de Navarra, Universidad de Navarra
M.D. Anderson Cancer Center
Shengjing Hospital
National Cancer Institute (NCI)
Pediatric Brain Tumor Consortium
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Massachusetts General Hospital
Augusta University
National Institutes of Health Clinical Center (CC)
Augusta University
The University of Texas Health Science Center, Houston
Jazz Pharmaceuticals
University of Florida
Seattle Children's Hospital
Seattle Children's Hospital
Universitätsklinikum Hamburg-Eppendorf
Universitätsklinikum Hamburg-Eppendorf
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GlaxoSmithKline
Milton S. Hershey Medical Center
Cedars-Sinai Medical Center
Nationwide Children's Hospital
University of Zurich
Mayo Clinic
Pediatric Brain Tumor Consortium
National Institutes of Health Clinical Center (CC)
Ourotech, Inc.
Hackensack Meridian Health